Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for ublituximab

  1. Ublituximab for treating relapsing multiple sclerosis (TA1025)

    Evidence-based recommendations on ublituximab (Briumvi) for treating relapsing multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    18 December 2024
    View recommendations

    Sections for TA1025

  2. Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]

    Discontinued Reference number: GID-TA10447

    Technology appraisal guidance
    Discontinued